# Efficacy and Safety of Neoadjuvant Therapy in Patients With Resectable HCC Screened by a Multimodal Deep Learning Model.

> **NCT06311916** · PHASE4 · NOT_YET_RECRUITING · sponsor: **Chen Xiaoping** · enrollment: 312 (estimated)

## Conditions studied

- HCC

## Interventions

- **DRUG:** HAIC + Tirelizumab +lenvatinib +liver resection
- **PROCEDURE:** liver resection

## Key facts

- **NCT ID:** NCT06311916
- **Lead sponsor:** Chen Xiaoping
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-05-01
- **Primary completion:** 2027-12-31
- **Final completion:** 2028-12-31
- **Target enrollment:** 312 (ESTIMATED)
- **Last updated:** 2024-03-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06311916

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06311916, "Efficacy and Safety of Neoadjuvant Therapy in Patients With Resectable HCC Screened by a Multimodal Deep Learning Model.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06311916. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*